Harpoon Therapy Inc. (HARP)
(Delayed Data from NSDQ)
$10.59 USD
-0.41 (-3.73%)
Updated May 3, 2019 04:13 PM ET
After-Market: $10.33 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[HARP]
Reports for Purchase
Showing records 21 - 40 ( 162 total )
Industry: Medical - Drugs
1Q2022 Update - Remaining Bullish on Platforms, and Increasing PT to $18
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Drugs
Industry: Medical - Drugs
Clinical Programs on Track in 2022; New TriTAC Platform Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
Q1 Financials; Update at ASCO for HPN328; Upgrading to OUTPERFORM on Valuation
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
4Q21 Update - ''424 Discontinued, PT to $14, But Remaining Very Bullish
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Drugs
Prostate Cancer Program Shelved; Lower PT to $18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Industry: Medical - Drugs
4Q Financials; Pipeline Refocused as HPN424 Discontinued
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Industry: Medical - Drugs
Sanofi''s Planned Acquisition of Amunix Hints at Harp''s Potential
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Drugs
Industry: Medical - Drugs
Backed by Validating Data, New CEO Outlines Plans to Drive Value in 2022
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Industry: Medical - Drugs
Pipeline Update Showcases Progress Across Platforms; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Industry: Medical - Drugs
Healthcare- Companies With YE2021 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: Research Department